Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: Relevance of Kohne's risk classification

被引:11
作者
Desot, Elise [1 ]
de Mestier, Louis [1 ]
Volet, Julien [1 ]
Delmas, Christelle [2 ]
Garcia, Bruno [3 ]
Geoffroy, Patrick [4 ]
Abdelli, Naceur [5 ]
Baule, Marielle [6 ]
Dubroeucq, Olivier [7 ]
Marquis, Eric [2 ]
Bouche, Olivier [1 ]
机构
[1] Univ Hosp Reims, Dept Hepatogastroenterol & Digest Oncol, F-51092 Reims, France
[2] Univ Hosp Reims, Clin Res Ctr, F-51092 Reims, France
[3] Polyclin Courlancy, Dept Hepatogastroenterol, Reims, France
[4] Clin St Vincent, Dept Hepatogastroenterol, Epernay, France
[5] Ctr Hosp Chalons En Champagne, Dept Hepatogastroenterol, Chalons Sur Marne, France
[6] Ctr Hosp Auban Moet, Dept Hepatogastroenterol, Epernay, France
[7] Inst Jean Godinot, Dept Digest Oncol, Reims, France
关键词
Colorectal neoplasm; Metastasis; Palliative chemotherapy; Prognosis; RANDOMIZED CONTROLLED-TRIAL; CETUXIMAB PLUS IRINOTECAN; PHASE-III; COMBINATION CHEMOTHERAPY; 1ST-LINE TREATMENT; INDIVIDUAL DATA; OXALIPLATIN; SURVIVAL; FLUOROURACIL; BEVACIZUMAB;
D O I
10.1016/j.dld.2012.10.016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Kohne's prognostic classification has been previously proposed, based on performance status, alkaline phosphatase level, number of metastatic sites and white blood cells count. Aims: To identify prognostic factors for survival and to assess the validity of Kohne's classification, in the era of targeted biotherapies, in patients treated with chemotherapy for non resectable metastatic colorectal cancer. Methods: A total of 290 consecutive patients were retrospectively identified in all gastroenterology units of one French county, between 2004 and 2008. Univariate and multivariate analysis for overall survival were performed using pre-treatment patient characteristics. Results: All data were available for prognostic categorization in 133 patients. Median survival was 22.1 months. The distribution and median survival for Kohne's prognostic groups were as following: good (n=73; 24.8 months), intermediate (n=35; 24.2 months), and poor (n=25; 7.0 months). The survival difference was significant between good and poor prognostic groups (p<0.01) and between intermediate and poor prognostic groups (p<0.01), but not between good and intermediate prognostic groups (p=0.5). The two independent prognostic factors of survival in multivariate analysis were performance status 0/1 (p<0.01) and white blood cells count <10 x 10(9)/L (p<0.01). Conclusions: The relevance of Kohne's classification is questioned. A simplified score could be validated by largest studies, based on white blood cells count and performance status. (C) 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:330 / 335
页数:6
相关论文
共 27 条
[1]   Cetuximab efficacy in patients treated routinely in university hospitals [J].
Bachet, Jean-Baptiste ;
Afchain, Pauline ;
Fermanian, Christophe ;
Bouchahda, Mohamed ;
Mitry, Ammanuel ;
Landi, Bruno ;
Andre, Thierry ;
Lievre, Astrid ;
Louvet, Christophe ;
Aegerter, Philippe ;
Levi, Francis ;
Rougier, Philippe .
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2007, 31 (11) :941-949
[2]   FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study [J].
Chibaudel, B. ;
Tournigand, C. ;
Artru, P. ;
Andre, T. ;
Cervantes, A. ;
Figer, A. ;
Lledo, G. ;
Flesch, M. ;
Buyse, M. ;
Mineur, L. ;
Carola, E. ;
Rivera, F. ;
Perez-Staub, N. ;
Louvet, C. ;
de Gramont, A. .
ANNALS OF ONCOLOGY, 2009, 20 (08) :1383-1386
[3]   Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study [J].
Chibaudel, Benoist ;
Bonnetain, Franck ;
Tournigand, Christophe ;
Bengrine-Lefevre, Leila ;
Teixeira, Luis ;
Artru, Pascal ;
Desrame, Jerome ;
Larsen, Annette K. ;
Andre, Thierry ;
Louvet, Christophe ;
de Gramont, Aimery .
ONCOLOGIST, 2011, 16 (09) :1228-1238
[4]   Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].
Cunningham, D ;
Humblet, Y ;
Siena, S ;
Khayat, D ;
Bleiberg, H ;
Santoro, A ;
Bets, D ;
Mueser, M ;
Harstrick, A ;
Verslype, C ;
Chau, I ;
Van Cutsem, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345
[5]   KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer [J].
De Roock, Wendy ;
De Vriendt, Veerle ;
Normanno, Nicola ;
Ciardiello, Fortunato ;
Tejpar, Sabine .
LANCET ONCOLOGY, 2011, 12 (06) :594-603
[6]  
Diaz Roberto, 2005, Clin Colorectal Cancer, V5, P197, DOI 10.3816/CCC.2005.n.031
[7]   Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].
Douillard, Jean-Yves ;
Siena, Salvatore ;
Cassidy, James ;
Tabernero, Josep ;
Burkes, Ronald ;
Barugel, Mario ;
Humblet, Yves ;
Bodoky, Gyoergy ;
Cunningham, David ;
Jassem, Jacek ;
Rivera, Fernando ;
Kocakova, Ilona ;
Ruff, Paul ;
Blasinska-Morawiec, Maria ;
Smakal, Martin ;
Canon, Jean-Luc ;
Rother, Mark ;
Oliner, Kelly S. ;
Wolf, Michael ;
Gansert, Jennifer .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705
[8]   Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial [J].
Ducreux, Michel ;
Malka, David ;
Mendiboure, Jean ;
Etienne, Pierre-Luc ;
Texereau, Patrick ;
Auby, Dominique ;
Rougier, Philippe ;
Gasmi, Mohamed ;
Castaing, Marine ;
Abbas, Moncef ;
Michel, Pierre ;
Gargot, Dany ;
Azzedine, Ahmed ;
Lombard-Bohas, Catherine ;
Geoffroy, Patrick ;
Denis, Bernard ;
Pignon, Jean-Pierre ;
Bedenne, Laurent ;
Bouche, Olivier .
LANCET ONCOLOGY, 2011, 12 (11) :1032-1044
[9]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[10]   Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk [J].
Kabbinavar, Fairooz ;
Irl, Cornelia ;
Zurlo, Alfredo ;
Hurwitz, Herbert .
ONCOLOGY, 2008, 75 (3-4) :215-223